[1] |
TANAKA T, NARAZAKI M, KISHIMOTO T. IL-6 in inflammation,immunity,and disease[J]. Cold Spring Harb Perspect Biol, 2014, 6(10):a016295.
|
[2] |
SCHULTZ N A, JOHANSEN J S. YKL-40-A protein in the field of translational medicine:a role as a biomarker in cancer patients?[J]. Cancers(Basel), 2010, 2(3):1453-1491.
|
[3] |
JOHANSEN J S, JENSEN B V, ROSLIND A, et al. Serum YKL-40,a new prognostic biomarker in cancer patients?[J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(2):194-202.
|
[4] |
OH I H, PYO J S, SON B K. Prognostic impact of YKL-40 immunohistochemical expression in patients with colorectal cancer[J]. Curr Oncol, 2021, 28(4):3139-3149.
|
[5] |
KIM S H, DAS K, NOREEN S, et al. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer[J]. World J Surg Oncol, 2007, 5:17.
|
[6] |
ZANONI D K, PATEL S G, SHAH J P. Changes in the 8th edition of the American Joint Committee on Cancer(AJCC) staging of head and neck cancer:rationale and implications[J]. Curr Oncol Rep, 2019, 21(6):52.
|
[7] |
SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics,2012[J]. CA Cancer J Clin, 2012, 62(1):10-29.
|
[8] |
KALAVREZOS N, BHANDARI R. Current trends and future perspectives in the surgical management of oral cancer[J]. Oral Oncol, 2010, 46(6):429-432.
|
[9] |
DUFFY S A, TAYLOR J M, TERRELL J E, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients[J]. Cancer, 2008, 113(4):750-757.
|
[10] |
MOJTAHEDI Z, KHADEMI B, HASHEMI S B, et al. Serum interleukine-6 concentration,but not interleukine-18,is associated with head and neck squamous cell carcinoma progression[J]. Pathol Oncol Res, 2011, 17(1):7-10.
|
[11] |
HAO W, ZHU Y, ZHOU H. Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer[J]. Med Oncol, 2013, 30(1):333.
|
[12] |
CHANG K P, KAO H K, WU C C, et al. Pretreatment interleukin-6 serum levels are associated with patient survival for oral cavity squamous cell carcinoma[J]. Otolaryngol Head Neck Surg, 2013, 148(5):786-791.
|
[13] |
YADAV A, KUMAR B, DATTA J, et al. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway[J]. Mol Cancer Res, 2011, 9(12):1658-1667.
|
[14] |
LEDERLE W, DEPNER S, SCHNUR S, et al. IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines[J]. Int J Cancer, 2011, 128(12):2803-2814.
|
[15] |
STANAM A, LOVE-HOMAN L, JOSEPH T S, et al. Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma[J]. Mol Oncol, 2015, 9(7):1371-1383.
|
[16] |
LYU X, ZHANG M, LI G, et al. Interleukin-6 production mediated by the IRE1-XBP1 pathway confers radioresistance in human papillomavirus-negative oropharyngeal carcinoma[J]. Cancer Sci, 2019, 110(8):2471-2484.
|
[17] |
BIAN B, LI L, YANG J, et al. Prognostic value of YKL-40 in solid tumors:a meta-analysis of 41 cohort studies[J]. Cancer Cell Int, 2019, 19:259.
|
[18] |
ROSLIND A, JOHANSEN J S, CHRISTENSEN I J, et al. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival[J]. Int J Cancer, 2008, 122(4):857-863.
|
[19] |
SHAO R, HAMEL K, PETERSEN L, et al. YKL-40,a secreted glycoprotein,promotes tumor angiogenesis[J]. Oncogene, 2009, 28(50):4456-4468.
|